Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aurora Cannabis Inc. is a Canadian-based cannabis company primarily engaged in the production, distribution, and sale of medical cannabis, with a secondary focus on select international markets. The company operates within the regulated cannabis industry, serving patients through prescription-based medical channels rather than broad consumer recreational markets. Aurora’s core revenue drivers are dried flower, medical cannabis oils, derivatives, and bulk cannabis sales to other licensed producers and international distributors.
Founded in 2006 as Aurora Marijuana Inc., the company initially focused on medical cannabis cultivation in Canada. It expanded rapidly following Canada’s legalization of adult-use cannabis in 2018, pursuing an aggressive growth and acquisition strategy. Over time, Aurora strategically retreated from large-scale recreational exposure, restructuring its operations to prioritize profitability, cost discipline, and leadership in high-quality medical cannabis. The company positions itself as a premium, science-driven supplier with expertise in genetics, cultivation, and pharmaceutical-grade production standards.
Business Operations
Aurora generates revenue primarily through its Medical Cannabis segment, which serves patients in Canada and internationally through controlled distribution channels. The company also maintains a Plant Propagation segment, which focuses on the production and sale of cannabis genetics and wholesale plant materials. Recreational cannabis activities have been significantly reduced and are not a core strategic focus. Aurora’s vertically integrated operations include cultivation, processing, product formulation, and distribution.
The company operates advanced cultivation and manufacturing facilities, including Aurora Sky, Aurora River, and Aurora Nordic, which support both domestic and export markets. Aurora owns several subsidiaries, including Aurora Cannabis Enterprises Inc., Whistler Medical Marijuana Corporation, and Aurora Deutschland GmbH, which enable market-specific operations and regulatory compliance. The company relies on proprietary genetics, automated cultivation technologies, and pharmaceutical-grade quality systems to differentiate its medical cannabis offerings.
Strategic Position & Investments
Aurora’s strategic direction emphasizes sustainable profitability, cash preservation, and leadership in global medical cannabis markets. The company has divested or shuttered non-core assets and reduced cultivation capacity to align supply with demand. Growth initiatives are centered on expanding high-margin international medical markets, advancing premium product offerings, and leveraging intellectual property in cannabis genetics and cultivation science.
Historically, Aurora completed several high-profile acquisitions, including CanniMed Therapeutics Inc., MedReleaf Corp., and Whistler Medical Marijuana Corporation, which strengthened its medical cannabis portfolio and patient base. The company continues to invest selectively in research, plant genetics, and pharmaceutical-grade production standards rather than large-scale capacity expansion. Exposure to emerging sectors such as cannabinoid research and next-generation medical formulations remains limited but strategically aligned with its medical focus.
Geographic Footprint
Aurora is headquartered in Canada, with primary operations and production facilities located in Alberta, Ontario, and Quebec. Canada remains the company’s largest single market, particularly within the medical cannabis channel. Internationally, Aurora has established a meaningful presence in Europe, where it supplies medical cannabis to markets such as Germany, Poland, and France under stringent regulatory frameworks.
Beyond Europe, Aurora has operational or distribution exposure in Australia, Israel, and select Latin American markets, primarily through exports and local partnerships. The company’s international footprint is designed to capitalize on early-stage medical cannabis legalization trends while avoiding heavy capital commitments in uncertain regulatory environments.
Leadership & Governance
Aurora is led by an experienced executive team with backgrounds in regulated industries, pharmaceuticals, and consumer packaged goods. The leadership philosophy emphasizes financial discipline, operational efficiency, and credibility with medical regulators and institutional stakeholders following a period of rapid expansion and restructuring.
Key executives include:
- Miguel Martin – Chief Executive Officer
- Chris Boudreau – Chief Financial Officer
- Dr. Michael Singer – Chief Medical Officer
- Darren Karasiuk – Senior Vice President, Corporate Development
- Shawn Deedman – Executive Vice President, Operations
The company is governed by a board of directors with experience in healthcare, capital markets, and international business, reflecting Aurora’s strategic focus on compliance-driven growth and long-term value creation.